KR101704996B1 - Composition comprising an extraction of Syzygium formosum for preventing or treating of allergy - Google Patents
Composition comprising an extraction of Syzygium formosum for preventing or treating of allergy Download PDFInfo
- Publication number
- KR101704996B1 KR101704996B1 KR1020160070800A KR20160070800A KR101704996B1 KR 101704996 B1 KR101704996 B1 KR 101704996B1 KR 1020160070800 A KR1020160070800 A KR 1020160070800A KR 20160070800 A KR20160070800 A KR 20160070800A KR 101704996 B1 KR101704996 B1 KR 101704996B1
- Authority
- KR
- South Korea
- Prior art keywords
- syzygium
- extract
- formosum
- food
- allergy
- Prior art date
Links
- 244000041431 Syzygium formosum Species 0.000 title claims abstract description 62
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 44
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 230000007815 allergy Effects 0.000 title claims abstract description 25
- 238000000605 extraction Methods 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 65
- 235000013305 food Nutrition 0.000 claims abstract description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 230000036541 health Effects 0.000 claims description 15
- 239000013566 allergen Substances 0.000 claims description 13
- 208000003455 anaphylaxis Diseases 0.000 claims description 13
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 230000036783 anaphylactic response Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 235000013376 functional food Nutrition 0.000 claims description 10
- 208000024780 Urticaria Diseases 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 7
- 201000008937 atopic dermatitis Diseases 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 235000013311 vegetables Nutrition 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 6
- 201000010105 allergic rhinitis Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 239000000835 fiber Substances 0.000 claims description 6
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 6
- 239000000118 hair dye Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims 2
- 208000024891 symptom Diseases 0.000 abstract description 32
- 230000000172 allergic effect Effects 0.000 abstract description 8
- 208000010668 atopic eczema Diseases 0.000 abstract description 8
- 208000004262 Food Hypersensitivity Diseases 0.000 description 39
- 235000020932 food allergy Nutrition 0.000 description 39
- 206010016946 Food allergy Diseases 0.000 description 34
- 238000011282 treatment Methods 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 210000000813 small intestine Anatomy 0.000 description 19
- 230000006698 induction Effects 0.000 description 18
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 17
- 239000000401 methanolic extract Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 12
- 229960003957 dexamethasone Drugs 0.000 description 11
- 206010012735 Diarrhoea Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 210000003979 eosinophil Anatomy 0.000 description 9
- 239000002504 physiological saline solution Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 210000003630 histaminocyte Anatomy 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 244000045719 Syzygium Species 0.000 description 5
- 235000012096 Syzygium samarangense Nutrition 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 230000007688 immunotoxicity Effects 0.000 description 4
- 231100000386 immunotoxicity Toxicity 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 3
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- 230000002052 anaphylactic effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010411 cooking Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- -1 olive oil Chemical compound 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 description 2
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 208000013385 food protein-induced enterocolitis syndrome Diseases 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010068355 Oral allergy syndrome Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000010454 developmental mechanism Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 229940089602 epinephrine injection Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000037851 severe atopic dermatitis Diseases 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 시지지움 포르모슘(Syzygium formosum) 추출물을 포함하는 알레르기 질환의 예방 또는 치료용 조성물에 관한 것이다. The present invention relates to a composition for preventing or treating an allergic disease comprising Syzygium formosum extract.
우리나라는 경제 발전과 함께 각종 알레르기 질환이 증가하고 있는 추세이다. 알레르기(allergy)는 과민반응이란 뜻으로, 생물체가 어떤 외래성 물질과 접하게 되어 항원-항체반응에 의하여 생체 내에서 급격한 반응이 일어나는 현상을 의미한다. 알레르기 반응을 유발하는 항원은 알레르겐(allergen)이라고 하며, 전형적인 알레르겐은 꽃가루, 약물, 식물성 섬유, 세균, 음식물, 염색약, 화학물질 등이 있다. In Korea, various allergic diseases are increasing along with economic development. Allergy is an allergic reaction that refers to a phenomenon in which an organism comes into contact with an exogenous substance and a rapid reaction occurs in vivo by an antigen-antibody reaction. Antigens that cause allergic reactions are called allergens. Typical allergens include pollen, drugs, vegetable fibers, bacteria, food, dyes, and chemicals.
최근에는 식품에 의해 유발되는 알레르기 질환에 대해 관심이 높아지고 있는데, 한 조사에 의하면 전 국민의 5~10%에서 식품과 관련된 알레르기 증상을 경험하였다고 한다(박용민, 2015). 식품에는 알레르겐 이외에 매우 다양한 생물학적 기능을 가진 성분과 첨가물이 포함되어 있고, 또 이들에 의해서 알레르기와 유사한 증상이 나타날 수 있기 때문에 식품으로 나타나는 증상을 포괄적으로 식품 유해 반응(adverse food reaction)이라고 한다. 식품 유해반응 중 면역학적 기전과 연관되어 나타나는 것을 식품 알레르기(food allergy)라고 한다(Sampson H.A., 2003).In recent years, interest in food-induced allergies has been growing. According to a survey, 5 to 10% of all people experience food-related allergies (Park, Yong-min, 2015). In addition to allergens, foods contain ingredients and additives with a wide variety of biological functions, and because they can cause symptoms similar to allergies, the symptoms that are expressed in foods are collectively called adverse food reactions. Food allergy is associated with an immunological mechanism during food harm (Sampson H.A., 2003).
지난 20년 간 식품 알레르기는 지속적인 증가를 보이며 중증도 또한 심해지고 있다(Norwak-Wegrzyn A., et al., 2006; Grundy J., et al., 2002). 식품 알레르기는 주로 영유아기에 가장 높은 발병을 보여 전체 영유아의 5~8%가 식품 알레르기를 나타내고 특히, 아토피 피부염 환자들에서 흔하며(Bock S.A., 1987; Venter C., et al., 2008), 나이가 들면서 현저히 감소한다(Kjaer H.F., et al., 2008; Venter C., et al., 2006). Over the past 20 years, food allergies have been steadily increasing and severity has also become worse (Norwak-Wegrzyn A., et al., 2006; Grundy J., et al., 2002). Food allergies are the most prevalent in infancy, with 5-8% of all infants presenting with food allergies, especially in atopic dermatitis patients (Bock SA, 1987; Venter C., et al., 2008) (Kjaer HF, et al., 2008; Venter C., et al., 2006).
식품 알레르기의 증상은 발생 기전에 따라 IgE(immunoglobulin E) 매개형, IgE/세포 복합 매개형, 세포 매개형으로 분류하여 설명할 수 있다(Norwak-Wegrzyn A., et al., 2006). The symptoms of food allergy can be categorized into IgE (immunoglobulin E), IgE / cell complex, and cell mediated according to the developmental mechanism (Norwak-Wegrzyn A., et al., 2006).
IgE 매개형 식품 알레르기는 경구관용의 실패로 생성된 특이 IgE에 의한 즉시형 면역반응으로 식품 섭취 후에 즉시 증상이 발생한다(Sampson H.A., 1999). 두드러기는 흔한 증상으로 단독으로 혹은 아나필락시스(anaphylaxis)의 증상으로 나타난다. 구강 알레르기 증후군은 특정 화분에 알레르기가 있는 환자가 생과일이나 야채를 섭취할 경우에 증상이 발생하며 대부분 입술부종이나 입 주위 가려움 정도로 경미하나 10% 정도에서는 후두부종을 보이고 매우 드물게 아나필락시스가 발생하는 경우도 있다(Ortolani C., et al., 1993). 아나필락시스의 증상은 일반적으로 수 초~2시간 내에 이상한 기분, 답답함, 오심, 구토, 복통, 기침 등이 나타나며 환자의 80% 이상에서 피부 증상을 보인다. IgE-mediated food allergy is an immediate immune response due to the specific IgE produced by the failure of oral tolerance, resulting in immediate symptoms following food ingestion (Sampson H.A., 1999). Urticaria is a common symptom, either alone or as a symptom of anaphylaxis. Oral allergy syndrome occurs when a patient with allergies to certain pollen is symptomatic when taking fresh fruits or vegetables. Most of them are mild as lips edema or itching around the mouth, but occasionally 10% show occipital lobe and very rarely anaphylaxis (Ortolani C., et al., 1993). Symptoms of anaphylaxis usually manifest as strange mood, tightness, nausea, vomiting, abdominal pain, coughing within a few seconds to two hours, with skin symptoms occurring in more than 80% of patients.
IgE 매개/세포 매개 복합 기전에 의해서는 아토피 피부염, 알레르기성 호산구 식도염(allergic eosinophilic esophagitis, AEE), 위장염(allergic eosinophilic gastroentertis, AEG) 등의 증상이 발생한다. 원인 식품 섭취 후 2시간 정도부터 증상이 나타나며 만성, 재발성의 경과를 보인다. 중등증/중증 아토피피부염의 35%에서 IgE 매개 식품 알레르기와 관련된다(Hill D.J., et al., 2008). 알레르기성 호산구 식도염 환자들은 주로 영유아나 소아기 환자들이며 지속적인 오심, 상복부 통증, 소화불량, 구토 등을 호소하며 제산제에 반응하지 않는다. 위장염도 어느 연령에서도 발생하나 영유아에서 가장 많고 위유문부의 폐쇄와 유사한 증상을 일으켜 구토, 복통이 나타나며 광범위한 부위를 침범할 경우에는 설사, 위장관 단백소실 등을 일으킬 수 있다. Allergic eosinophilic esophagitis (AEE), allergic eosinophilic gastroenteritis (AEG), and other symptoms may occur due to IgE mediated / cell mediated complex mechanisms. Causes Symptoms appear from about 2 hours after ingestion of food and show chronic and recurrent course. It is associated with IgE-mediated food allergies in 35% of moderate / severe atopic dermatitis (Hill D.J., et al., 2008). Patients with allergic eosinophilic esophagitis are mainly infants and children and they complain of persistent nausea, abdominal pain, indigestion, vomiting, and do not respond to antacids. Gastroenteritis occurs in any age, but it is the most common in infants and children. It causes vomiting and abdominal pain due to symptoms similar to the obstruction of the stomach pylorus. Invasion of a wide area can cause diarrhea and gastrointestinal protein loss.
세포 매개형 기전에 의해서는 식품단백 직장염(food protein-induced protocolitis, FPP)과 식품단백 장염증후군(food protein-induced enterocolitis syndrome, FPIES)이 발생한다. 식품단백 직장염은 주로 대장상피와 고유상피(laminal propria)에 호산구의 침윤과 부종이 나타난다. 식품단백 장염증후군의 경우에는 구토, 설사가 나타나며 심한 경우에는 복수, 성장 장애를 일으킨다. 식품단백질 장염증후군은 TGF-β(transforming growth factor-β) 분비의 감소와 식품 항원에 특이적인 T 세포의 TNF-α(tumor necrosis factor-α) 분비에 의한 장점막의 부종 및 염증과 관련이 있다. 원인 식품의 섭취 1~3시간 후부터 구토, 설사가 시작되고 심한 경우에는 저혈압이 나타날 수 있다(Sicherer S.H., 2005). The cell-mediated mechanism leads to food protein-induced protocolitis (FPP) and food protein-induced enterocolitis syndrome (FPIES). Food proteinuritis is characterized by infiltration of eosinophils and edema in the colon epithelium and lamina propria. In the case of food proteinuria syndrome, vomiting and diarrhea are present. Food proteinuria syndrome is associated with a decrease in TGF-β (transforming growth factor-β) secretion and edema and inflammation of the intestinal mucosa due to TNF-α secretion in food-antigen-specific T cells. Cause Causes vomiting and diarrhea 1 to 3 hours after ingestion of food and hypotension may occur in severe cases (Sicherer S. H., 2005).
식품 알레르기에 대한 치료는 원인식품 제거, 증상이 있을 경우 증상의 치료, 적절한 영양 공급이다. 증상의 치료에서는 두드러기나 아토피 피부염과 같은 피부증상은 항히스타민제를 투여한다. 기관지 수축에 의한 쌕쌕거림이나 기침이 있는 경우는 기관지 확장제를 사용할 수 있다. 식품에 의한 급성 아나필락시스 반응의 경우에는 즉각적인 처치가 필요하며 에피네프린 근육 주사를 통해 증상을 치료할 수 있다(최선희, et al., 2009).Treatment for food allergies is the elimination of causative foods, symptomatic treatment of symptoms, and adequate nutrition. In the treatment of symptoms, skin symptoms such as urticaria and atopic dermatitis are treated with antihistamines. Bronchodilator may be used when there is wheezing or coughing due to bronchoconstriction. In the case of acute anaphylactic reactions caused by food, immediate treatment is needed and epinephrine injection can be used to treat the symptoms (Choi, Sunhee, et al., 2009).
식품 알레르기에 대한 새로운 치료법으로 항원 특이면역 요법, 유전자 조작 단백질을 이용한 면역 요법과 항IgE(anti-IgE), 항IL-5(anti-IL-5) 등을 이용한 항염증 요법 등이 연구 중이다(Sicherer S.H., et al., 2009).Anti-inflammatory therapies such as antigen-specific immunotherapy, immunotherapy using genetically engineered proteins, anti-IgE (anti-IgE) and anti-IL-5 (anti-IL-5) Sicherer SH, et al., 2009).
시지지움 포르모슘(Syzygium formosum)은 방글라데시, 인도, 미얀마, 태국, 라오스, 베트남 등과 같은 동남아시아에서 서식하는 상록수로 10m 높이까지 성장한다. 베트남과 라오스에서는 시지지움 포르모슘(Syzygium formosum)을 재배하여 이 나무의 과일을 식용으로 이용하고 있다. 또한, 베트남에서는 건조시킨 시지지움 포르모슘(Syzygium formosum)의 잎에 물을 가하여 얻은 물 추출물을 아토피성 피부 질환 및 위장 장애 치료에 이용하고 있다. Syzygium formosum grows up to 10 meters in height, growing in Southeast Asia, such as Bangladesh, India, Myanmar, Thailand, Laos and Vietnam. In Vietnam and Laos, Syzygium formosum is cultivated and the fruit of this tree is used for food. In Viet Nam, water extracts obtained by adding water to dried leaves of Syzygium formosum are used for the treatment of atopic skin diseases and gastrointestinal disorders.
이에, 본 발명자는 시지지움 포르모슘(Syzygium formosum) 추출물의 효능을 연구하던 중, 건조된 시지지움 포르모슘(Syzygium formosum) 잎에 메탄올 가하여 추출한 메탄올 추출물을 식품 알레르기를 유도한 마우스 모델에 투여하면 알레르기에 의해 유도된 증상들이 개선 또는 치료되는 것을 확인함으로써 본 발명을 완성할 수 있었다. Thus, the present inventors have found that Syzygium formosum ) extracts, the dried Syzygium Formosum leaves obtained by adding methanol to a mouse model inducing food allergy, the inventors confirmed that the symptoms induced by allergy are improved or treated, thereby completing the present invention.
종래 선행기술로서 한국공개특허 제2013-0068307호에는 시지지움 포르모슘(Syzygium formosum)의 물, 알코올 또는 이들의 혼합용매를 이용하여 추출한 추출물이 기재되어 있으나, 탈모, 소화성궤양, 구내염 또는 구강궤양, 창상 및 화상, 골절 또는 말초혈관질환의 치료용 조성물로, 본 발명의 알레르기의 예방 또는 치료용 조성물과는 차이가 있다. Korean Patent Laid-Open Publication No. 2013-0068307 discloses extracts of Syzygium formosum using water, alcohol, or a mixed solvent thereof. However, it is also possible to use extracts obtained from alopecia, peptic ulcer, Wound, burn, fracture or peripheral vascular disease, which is different from the composition for preventing or treating allergy of the present invention.
본 발명의 목적은 시지지움 포르모슘(Syzygium formosum) 추출물을 포함하는 알레르기 질환의 예방 또는 치료용 조성물을 제공하는 데 있다. It is an object of the present invention to provide a composition for preventing or treating an allergic disease comprising Syzygium formosum extract.
본 발명은 시지지움 포르모슘(Syzygium formosum) 추출물을 포함하는 알레르기 질환의 예방 또는 치료용 조성물에 관한 것이다. The present invention relates to a composition for preventing or treating an allergic disease comprising Syzygium formosum extract.
상기 추출물은 시지지움 포르모슘(Syzygium formosum)의 잎에 물, C1 내지 C4의 저급 알코올 또는 이들의 혼합용액을 용매로 하여 추출한 추출물을 포함하는 알레르기 질환의 예방 또는 치료용 조성물일 수 있다. The extract may be a composition for preventing or treating an allergic disease comprising extracts of leaves of Syzygium formosum using water, C1 to C4 lower alcohols or a mixed solution thereof as a solvent.
상기 추출물은 시지지움 포르모슘(Syzygium formosum)의 잎에 메탄올을 용매로 하여 추출한 추출물을 포함하는 알레르기 질환의 예방 또는 치료용 조성물일 수 있다. The extract may be a composition for preventing or treating an allergic disease comprising an extract of methanol extract of Syzygium formosum with methanol as a solvent.
상기 알레르기는 꽃가루, 약물, 식물성 섬유, 세균, 식품, 염색약 및 화학 물질로 이루어진 군에서 선택되는 1종 이상에 의해 유도되는 알레르기 질환의 예방 또는 치료용 조성물일 수 있다. The allergy may be a composition for preventing or treating allergic diseases induced by at least one selected from the group consisting of pollen, drug, vegetable fiber, bacteria, food, hair dye, and chemical substances.
상기 알레르기는 식품에 의해 유도되는 알레르기 질환의 예방 또는 치료용 조성물일 수 있다. The allergy may be a composition for preventing or treating food allergy-induced allergic diseases.
상기 알레르기 질환은 두드러기, 아나필락시스, 알레르기성 비염, 기관지천식 및 아토피성 피부염으로 이루어진 군에서 선택되는 1종 이상인 것을 특징으로 하는 알레르기 질환의 예방 또는 치료용 조성물 일 수 있다. The allergic disease may be at least one selected from the group consisting of urticaria, anaphylaxis, allergic rhinitis, bronchial asthma, and atopic dermatitis.
또한, 본 발명은 시지지움 포르모슘(Syzygium formosum) 추출물을 포함하는 알레르기 질환의 예방 또는 개선용 건강기능식품에 관한 것이다. The present invention also relates to a health functional food for preventing or ameliorating an allergic disease comprising Syzygium formosum extract.
상기 추출물은 시지지움 포르모슘(Syzygium formosum)의 잎에 물, C1 내지 C4의 저급 알코올 또는 이들의 혼합용액을 용매로 하여 추출한 추출물을 포함하는 알레르기 질환의 예방 또는 개선용 건강기능식품일 수 있다. The extract may be a health functional food for preventing or ameliorating an allergic disease, which comprises extracts of Syzygium formosum leaves with water, C1 to C4 lower alcohol or a mixed solution thereof as a solvent.
상기 추출물은 시지지움 포르모슘(Syzygium formosum)의 잎에 메탄올을 용매로 하여 추출한 추출물을 포함하는 알레르기 질환의 예방 또는 개선용 건강기능식품일 수 있다. The extract may be a health functional food for preventing or ameliorating allergic diseases including extracts of methanol extract of Syzygium formosum using methanol as a solvent.
상기 알레르기는 꽃가루, 약물, 식물성 섬유, 세균, 식품, 염색약 및 화학 물질로 이루어진 군에서 선택되는 1종 이상에 의해 유도되는 알레르기 질환의 예방 또는 개선용 건강기능식품일 수 있다. The allergy may be a health functional food for preventing or ameliorating an allergic disease induced by at least one selected from the group consisting of pollen, drug, vegetable fiber, bacteria, food, hair dye, and chemical substances.
상기 알레르기는 식품에 의해 유도되는 알레르기 질환의 예방 또는 개선용 건강기능식품일 수 있다. The allergy may be a health functional food for preventing or improving food allergy-induced allergic diseases.
상기 알레르기 질환은 두드러기, 아나필락시스, 알레르기성 비염, 기관지천식 및 아토피성 피부염으로 이루어진 군에서 선택되는 1종 이상인 것을 특징으로 하는 알레르기 질환의 예방 또는 개선용 건강기능식품일 수 있다. The allergic disease may be one or more selected from the group consisting of urticaria, anaphylaxis, allergic rhinitis, bronchial asthma, and atopic dermatitis.
이하 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
상기 시지지움 포르모슘(Syzygium formosum) 추출물은 시지지움 포르모슘(Syzygium formosum)의 잎에 물, C1 내지 C4의 저급 알코올 또는 이들의 혼합용액을 용매로 하여 추출할 수 있으며, 상기 C1 내지 C4의 저급 알코올은 메탄올(methanol), 에탄올(ethanol), 프로판올(propanol), 이소프로판올(isopropanol), 부탄올(butanol) 및 이소부탄올(isobutanol)로 이루어진 군에서 선택될 수 있다. 바람직하게는 메탄올 수용액 또는 에탄올 수용액 일 수 있다.The Syzygium formosum extract may be extracted with water, a C1 to C4 lower alcohol, or a mixed solution thereof in the leaves of Syzygium formosum as a solvent. The C1 to C4 lower The alcohol may be selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol, and isobutanol. Preferably an aqueous solution of methanol or an aqueous solution of ethanol.
상기 메탄올 수용액은 50% 내지 70%의 메탄올 수용액 일 수 있다. The methanol aqueous solution may be an aqueous 50% to 70% methanol solution.
상기 에탄올 수용액은 50% 내지 70%의 에탄올 수용액 일 수 있다. The aqueous ethanol solution may be an aqueous 50% to 70% ethanol solution.
상기 시지지움 포르모슘(Syzygium formosum) 추출물은 에탄올, 아이소프로판올 또는 부탄올 추출물의 경우에도 메탄올 추출물과 비슷한 알레르기 증상의 개선 또는 치료 효과가 있다.The above-mentioned Syzygium formosum extract has the effect of improving or treating the allergy symptom similar to the methanol extract even in the case of ethanol, isopropanol or butanol extract.
상기 알레르기는 알레르기 유발 물질인 알레르겐과의 접촉을 통해 항원-항체 반응에 의하여 생체 내에서 급격한 반응이 일어나는 현상을 의미하는 것으로, 알레르겐은 꽃가루, 약물, 식물성 섬유, 세균, 식품, 염색약 및 화학 물질로 이루어진 군중에서 선택되는 1종 이상일 수 있으며, 바람직하게는 식품일 수 있으며, 이에 한정하는 것은 아니다. The allergen refers to a phenomenon in which a rapid reaction occurs in vivo by an antigen-antibody reaction through contact with an allergen which is an allergen-inducing substance. The allergen is a substance that reacts with pollen, drug, vegetable fiber, bacteria, food, And may be at least one kind selected from the group consisting of, preferably, food, but is not limited thereto.
또한, 상기 알레르기 질환은 알레르기에 의해 생기는 질환으로, 주된 질환은 기관지천식, 알레르기성 비염, 두드러기, 약진, 약제 알레르기, 혈청병 등이고, 알레르겐의 종류나 알레르기 반응을 일으키는 조직에 따라 여러 가지 질환의 유형을 나타낸다. In addition, the above-mentioned allergic diseases are diseases caused by allergies, and the main diseases are bronchial asthma, allergic rhinitis, urticaria, leukemia, drug allergies and serum diseases, and various types of diseases depending on the kind of allergens or tissues causing allergic reactions .
상기 알레르기 질환은 두드러기, 아나필락시스, 알레르기성 비염, 기관지천식 및 아토피성 피부염으로 이루어진 군 중에서 선택되는 1종 이상일 수 있다.The allergic disease may be at least one selected from the group consisting of urticaria, anaphylaxis, allergic rhinitis, bronchial asthma and atopic dermatitis.
또한, 본 발명은 시지지움 포르모슘(Syzygium formosum)을 포함하는 알레르기 질환의 예방 또는 치료용 약학 조성물을 제공한다. 상기 약학 조성물에는 시지지움 포르모슘(Syzygium formosum) 잎 추출물이 0.001 내지 100 중량%로 함유될 수 있다. 상기 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 상기 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 시지지움 포르모슘(Syzygium formosum) 잎 추출물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 탄산칼슘, 수크로스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. The present invention also provides a pharmaceutical composition for preventing or treating an allergic disease comprising Syzygium formosum . The pharmaceutical composition may contain 0.001 to 100% by weight of Syzygium formosum leaf extract. The pharmaceutical compositions may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to conventional methods. Examples of carriers, excipients and diluents that can be contained in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , Methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain at least one excipient in the Syzygium formosum leaf extract of the present invention, for example starch , Calcium carbonate, sucrose or lactose, and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명의 약학 조성물의 투여량은 치료받을 대상의 연령, 성별, 체중과, 치료할 특정 질환 또는 병리 상태, 질환 또는 병리 상태의 심각도, 투여경로 및 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있으며, 일반적으로 투여량은 0.01㎎/㎏/일 내지 대략 2000㎎/㎏/일의 범위이다. 더 바람직한 투여량은 1㎎/㎏/일 내지 500㎎/㎏/일이다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. The dosage of the pharmaceutical composition of the present invention will depend on the age, sex, body weight of the subject to be treated, the particular disease or condition to be treated, the severity of the disease or condition, the route of administration and the judgment of the prescriber. Dosage determinations based on these factors are within the level of ordinary skill in the art and generally the dosage ranges from 0.01 mg / kg / day to approximately 2000 mg / kg / day. A more preferable dosage is 1 mg / kg / day to 500 mg / kg / day. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.
본 발명의 약학 조성물은 쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사에 의해 투여될 수 있다. 본 발명의 화합물은 독성 및 부작용이 거의 없으므로 예방 목적으로 장기간 복용 시에도 안심하고 사용할 수 있는 약제이다. The pharmaceutical composition of the present invention can be administered to mammals such as rats, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection. Since the compound of the present invention has little toxicity and side effects, it can be safely used even for long-term administration for preventive purposes.
또한, 본 발명은 시지지움 포르모슘(Syzygium formosum) 추출물 및 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 알레르기 질환의 예방 또는 개선용 건강기능식품을 제공한다. 상기 시지지움 포르모슘(Syzygium formosum) 추출물은 본 발명의 건강기능식품에 0.001~100 중량%로 하여 첨가될 수 있다. 본 발명의 건강기능식품은 정제, 캡슐제, 환제 또는 액제 등의 형태를 포함하며, 본 발명의 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제 등이 있다. The present invention also provides a health functional food for preventing or ameliorating an allergic disease, comprising Syzygium formosum extract and a pharmaceutically acceptable food-aid additive. The Syzygium formosum extract may be added to the health functional food of the present invention in an amount of 0.001 to 100% by weight. The health functional food of the present invention includes forms such as tablets, capsules, pills, and liquids. Examples of the foods to which the extract of the present invention can be added include various foods, beverages, gums, tea, vitamins .
본 발명은 시지지움 포르모슘(Syzygium formosum) 추출물을 포함하는 알레르기 질환의 예방 또는 치료용 조성물에 관한 것으로, 식품 알레르기가 유도된 마우스 모델에 시지지움 포르모슘(Syzygium formosum) 잎의 메탄올 추출물을 투여하면 알레르기에 의한 증상들이 완화 및 치료되는 것을 확인하였다. The present invention relates to a composition for preventing or treating an allergic disease comprising Syzygium formosum extract, wherein a methanol extract derived from Syzygium formosum leaves is administered to a mouse model in which food allergy is induced It was confirmed that allergic symptoms were alleviated and treated.
이에 따라, 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물이 알레르기 질환의 예방 또는 치료 조성물로써 활용 가치가 높을 것으로 기대된다. Accordingly, the Syzygium formosum extract of the present invention is expected to be highly useful as a composition for the prevention or treatment of allergic diseases.
도 1은 식품 알레르기 유도 및 시지지움 포르모슘(Syzygium pormosum) 추출물의 처리에 따른 알레르기 증상의 변화를 보여주고 있다. A의 경우 직장 온도의 변화를, B는 아나필락시스 증상 완화 또는 치료 정도를, C는 설사 증상에 대한 점수를 D는 대변 형태의 변화를 보여주고 있다.
도 2는 식품 알레르기 유도 및 본 발명의 시지지움 포르모슘(Syzygium pormosum) 추출물의 처리에 따른 면역독성의 변화를 보여주고 있다. A 및 B는 면역독성으로 인한 비장의 크기 변화를 보여주고 있고, C는 장간막 림프절의 세포 충실도 변화를 보여주고 있다.
도 3은 식품 알레르기 유도 및 본 발명의 시지지움 포르모슘(Syzygium pormosum) 추출물의 처리에 따른 소장의 점막하 조직 변화를 보여주고 있다.
도 4는 식품 알레르기 유도 및 본 발명의 시지지움 포르모슘(Syzygium pormosum) 추출물의 처리에 따른 소장에서의 비만세포 수의 변화를 보여주고 있다.
도 5는 식품 알레르기 유도 및 본 발명의 시지지움 포르모슘(Syzygium pormosum) 추출물의 처리에 따른 소장에서의 호산구 침윤 변화를 보여주고 있다. Figure 1 shows changes in allergic symptoms due to the treatment of food allergy induction and Syzygium pormosum extract. A is the change in rectal temperature, B is anaphylactic symptom relief or treatment degree, C is diarrhea score, and D is the change of stool type.
Fig. 2 shows changes in immunotoxicity due to the induction of food allergy and the treatment of Syzygium pormosum extract of the present invention. A and B show changes in the size of the spleen due to immunotoxicity, and C shows changes in cell fidelity of mesenteric lymph nodes.
FIG. 3 shows the submucosal changes of the small intestine according to the induction of food allergy and the treatment of Syzygium pormosum extract of the present invention.
FIG. 4 shows changes in the number of mast cells in the small intestine according to the induction of food allergy and the treatment of Syzygium pormosum extract of the present invention.
Fig. 5 shows changes in eosinophil infiltration in the small intestine following the induction of food allergy and the treatment of the Syzygium pormosum extract of the present invention.
이하 본 발명의 바람직한 실시예를 상세히 설명하기로 한다. 그러나, 본 발명은 여기서 설명되는 실시예에 한정되지 않고 다른 형태로 구체화될 수도 있다. 오히려, 여기서 소개되는 내용이 철저하고 완전해지고, 당업자에게 본 발명의 사상을 충분히 전달하기 위해 제공하는 것이다.Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein but may be embodied in other forms. Rather, the intention is to provide an exhaustive, complete, and complete disclosure of the principles of the invention to those skilled in the art.
<실시예 1. 시지지움 포르모슘(EXAMPLES Example 1 [ Syzygium formosumSyzygium formosum ) 추출물 제조> ) Preparation of extract>
시지지움 포르모슘(Syzygium formosum) 잎은 신선한 잎을 채취하여 자연건조 시킨 것을 이용하였다. Syzygium formosum leaves were freshly harvested and dried.
건조된 시지지움 포르모슘(Syzygium formosum) 잎 200g을 막자사발을 이용하여 빻은 후 플라스크에 넣고, 메탄올 1ℓ를 가하여 60℃ 항온수조 상에서 3시간 동안 교반한 후 여과지(Whatman)로 여과하였다. 여과하여 남은 잎의 잔여물에 새로운 메탄올 1ℓ를 가하여 위의 추출 과정을 총 3회 반복하여 실시하여 메탄올 추출물 3ℓ를 얻었다. 얻은 메탄올 추출물을 진공회전농축기(rotary evaporator)를 이용하여 분말 형태의 메탄올 추출물 12g을 얻었다. 200 g of dried Syzygium formosum leaves were ground with a mortar and placed in a flask, and 1 L of methanol was added thereto. The mixture was stirred for 3 hours in a constant temperature water bath at 60 ° C., and then filtered with a filter paper (Whatman). After filtration, 1 liter of fresh methanol was added to the remaining leaves, and the above extraction procedure was repeated three times in total to obtain 3 liters of methanol extract. The obtained methanol extract was subjected to a rotary evaporator to obtain 12 g of a methanol extract in powder form.
시지지움 포르모슘(Syzygium formosum) 메탄올 추출물 사용 시에는 건조된 메탄올 추출물을 생리식염수(saline solution) 또는 0.5% 트윈-20(tween-20)이 포함된 생리식염수에 녹여서 사용하였다. 생리식염수에 녹일 경우에는 메탄올 추출물을 생리식염수에 녹인 후 0.2㎛의 필터로 필터링하여 사용하였다. 0.5% 트윈-20이 포함된 생리식염수에 녹일 경우에는 메탄올 추출물에 트윈-20을 넣고 녹인 후 생리식염수를 넣어주었다. Syzygium formosum methanol extract, the dried methanol extract was dissolved in physiological saline containing saline solution or 0.5% tween-20. When dissolved in physiological saline, the methanol extract was dissolved in physiological saline and filtered through a 0.2 μm filter. When dissolved in physiological saline containing 0.5% Tween-20, Tween-20 was added to the methanol extract, dissolved and physiological saline was added.
<실험예 1. 식품 알레르기 마우스 모델의 제조 및 추출물의 투여>EXPERIMENTAL EXAMPLE 1 Preparation of mouse model of food allergy and administration of extracts [
식품 알레르기 마우스 모델을 제조하기 위해 6주령의 수컷 BALB/C 마우스를 이용하였고(50마리), 알레르기 유도물질(알레르겐, allergen)로 닭의 난백알부민(ovalbumin)을 이용하였다.A 6-week-old male BALB / C mouse was used (50 animals) to produce a food allergic mouse model, and chicken ovalbumin was used as an allergen.
마우스의 면역을 유도(immunization)하기 위해 0.5㎎의 난백알부민을 2㎎의 명반(alum)과 혼합하여 2주 간격으로 2회, 쥐의 복강 내로 주사하였다. 2번째 면역유도를 위해 주사한 후 1주일 뒤에 쥐의 혈액을 채취하여 난백알부민 특이적인 IgG의 양을 측정하였다. In order to immunize mice, 0.5 mg of albumin albumin was mixed with 2 mg alum and injected into the abdominal cavity of mice twice at intervals of 2 weeks. One week after the injection for the second immunization induction, the blood of the rats was collected and the amount of IgG specific for egg albumin was measured.
식품 알레르기는 2번째 면역유도 주사 후 2주 뒤에 50㎎의 난백알부민을 3일 간격으로 5회 경구 투여함으로써 알레르기 반응이 일어나도록 유도하였다. The food allergy was induced to induce an allergic reaction by administering 50 mg of albumin albumin two times a week after the second immunization induction injection at 5 days intervals at intervals of 3 days.
또한, 알레르기 치료 효과를 확인하기 위해 시지지움 포르모슘(Syzygium formosum) 메탄올 추출물을 식품 알레르기 유발을 위해 50㎎ 난백알부민을 투여하는 동안 매일 경구 투여하였다. 이때, 양성대조군으로 덱사메타손(dexamethasone) 0.6㎎을 매일 투여하였다. 50㎎ 난백알부민 단독 또는 시지지움 포르모슘(Syzygium formosum) 메탄올 추출물을 마지막으로 투여 한 후에 알레르기에 의한 증상들을 관찰하였다. In order to confirm the effect of allergy treatment, methanol extract of Syzygium formosum was orally administered daily during the administration of 50 mg of albumin albumin for inducing food allergy. At this time, 0.6 mg of dexamethasone was administered daily as a positive control. After the last administration of 50 mg albumin albumin alone or methanol extract of Syzygium formosum , allergic symptoms were observed.
각 실험 그룹 당 마우스를 6마리 이용하였고, 각각의 실험 그룹을 하기 표 1에 나타내었다. Six mice were used for each experimental group, and the respective experimental groups are shown in Table 1 below.
<실험예 2. 식품 알레르기 증상의 개선 효과 확인>Experimental Example 2. Identification of Improvement Effect of Food Allergy Symptoms [
실험예 2-1. 직장(rectal) 온도 변화 확인Experimental Example 2-1. Check rectal temperature changes
식품 알레르기 유발 및 약물 처리에 따른 직장의 온도 변화를 확인하기 위해 각 그룹에 해당되는 마우스를 이용해 직장의 온도를 측정하였다. 직장 온도는 직장체온계의 센서 끝을 직장에 삽입하여 측정하였고, 그 결과를 도 1A에 나타내었다. The temperature of the rectum was measured using a mouse corresponding to each group in order to confirm the temperature change of rectum due to food allergen induction and drug treatment. Rectal temperature was measured by inserting the sensor tip of the rectal thermometer into the rectum and the results are shown in Figure 1A.
도 1A에서 보여주듯이, 식품 알레르기 유도 그룹(G2)의 경우에는 정상 그룹(G1)에 비해 직장 온도가 낮아진 것을 알 수 있다. 그러나 덱사메타손(G3) 또는 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물(G4~G7)을 처리한 그룹에서는 정상 그룹과 비슷한 수준의 직장 온도를 나타내는 것을 알 수 있다. As shown in FIG. 1A, in the case of the food allergy induction group (G2), the rectal temperature is lower than that of the normal group (G1). However, it can be seen that the group treated with dexamethasone (G3) or the Syzygium formosum extract (G4 to G7) of the present invention exhibits a rectal temperature similar to that of the normal group.
이를 통해, 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물이 알레르기 유발에 의해 나타나는 증상 중의 하나인 직장 온도 저하를 개선한다는 것을 알 수 있었다. Thus, it can be seen that the Syzygium formosum extract of the present invention improves rectal temperature lowering, which is one of the symptoms caused by allergy induction.
실험예 2-2. 아나필락시스(anaphylaxis) 관찰Experimental Example 2-2. Observation of anaphylaxis
본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물의 식품 알레르기에 의한 아나필락시스 증상 개선 또는 치료 효과를 확인하기 위해, 실험 그룹별 마우스 반응을 관찰하였고, 하기 표 2에 따라 아나필락시스 증상을 점수화하였다. 그 결과를 도 1B에 나타내었다. In order to confirm the effect of the Syzygium formosum extract of the present invention on the improvement or treatment of anaphylactic symptoms due to food allergy, mouse responses according to experimental groups were observed and the symptoms of anaphylactic reactions were scored according to Table 2 below. The results are shown in Fig. 1B.
도 1B에서 보여주듯이, 식품 알레르기 유도 그룹(G2)의 경우에는 정상 그룹(G1)에 비해 아나필락시스 점수가 높은 것을 알 수 있다. 그러나 덱사메타손(G3) 또는 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물(G4~G7)을 처리한 그룹의 아나필락시스 점수는 식품 알레르기 유도 그룹(G2)에 비해 낮은 것을 알 수 있다.As shown in FIG. 1B, the food allergy induction group (G2) has an anaphylactic score higher than that of the normal group (G1). However, it can be seen that the anaphylaxis score of the group treated with dexamethasone (G3) or the Syzygium formosum extract (G4 to G7) of the present invention is lower than that of the food allergy inducing group (G2).
이를 통해, 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물이 알레르기 유발에 의한 아나필락시스 증상을 개선한다는 것을 알 수 있었다.Thus, it can be seen that the Syzygium formosum extract of the present invention improves symptoms of anaphylactic reactions caused by allergy.
실험예 2-2. 대장에서의 대변(stool) 관찰Experimental Example 2-2. Observation of stool in the large intestine
본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물의 식품 알레르기에 의한 대변 형태 변화를 관찰하였다. 실험 그룹별 마우스의 대장 내의 대변의 형태를 육안으로 관찰하였고, 하기 표 3에 따라 설사 증상을 점수화하였다. 그 결과를 도 1C 및 도 1D에 나타내었다. Syphilium formosum extract of the present invention was observed to change the shape of the stool due to food allergy. The shape of the feces in the large intestine of the mice was visually observed according to the experimental group, and the diarrhea symptoms were scored according to the following Table 3. The results are shown in Figs. 1C and 1D.
도 1C에서 보여주듯이, 식품 알레르기 유도 그룹(G2)의 경우에는 정상 그룹(G1)에 비해 설사 증상에 대한 점수가 높은 것을 알 수 있다. 그러나 덱사메타손(G3) 또는 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물(G4~G7)을 처리한 그룹의 설사 증상에 대한 점수는 식품 알레르기 유도 그룹(G2)에 비해 낮은 것을 알 수 있다. As shown in FIG. 1C, the score of the diarrhea symptom is higher in the food allergy induction group (G2) than in the normal group (G1). However, the group treated with dexamethasone (G3) or the Syzygium formosum extract (G4 to G7) of the present invention has a lower score for diarrhea symptoms than the food allergy inducing group (G2).
또한, 도 1D의 대장에서의 대변의 형태를 관찰한 경우에도 식품 알레르기 유도 그룹(G2)에서는 고체의 대변 형태가 보이지 않고 묽은 변 형태가 관찰되었다. 반면, 덱사메타손(G3) 또는 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물(G4, G5)을 처리한 그룹에서는 정상 그룹(G1)와 유사하게 고체의 대변 형태를 관찰할 수 있었다. Further, even when the shape of the feces in the large intestine of Fig. 1D was observed, a solid feces pattern was not observed in the food allergy induction group (G2), and a dilute feces pattern was observed. On the other hand, in the group treated with dexamethasone (G3) or the Syzygium formosum extract (G4, G5) of the present invention, a fecund pattern of a solid was observed similarly to the normal group (G1).
이를 통해, 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물이 알레르기 유발에 의한 설사 증상을 개선한다는 것을 알 수 있었다. Thus, it can be seen that the Syzygium formosum extract of the present invention improves diarrhea caused by allergy.
<실험예 3. 면역 독성 확인><Experimental Example 3> Identification of immunotoxicity>
덱사메타손의 경우 항-알레르기 효과를 가지고 있지만, 면역세포 사멸 및 림프 기관의 퇴화를 유발하는 경향이 있다. 따라서, 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물의 항-알레르기 효과가 면역 독성을 수반하는지 확인하기 위해 비장의 크기 및 배수림프절, 즉 장간막 림프절의 세포충실도(cellularity)를 분석하였다. Dexamethasone has an anti-allergic effect, but tends to cause immune cell death and lymphatic organ degeneration. Therefore, in order to confirm whether the anti-allergic effect of the Syzygium formosum extract of the present invention is accompanied by immunotoxicity, the size of the spleen and the cellularity of the multiple lymph node, i.e. mesenteric lymph node, were analyzed.
상기 실험예 1의 각 실험 그룹의 마우스를 마취한 후 개복하여 비장 크기 및 장간막 림프절의 세포충실도를 관찰하였고, 그 결과를 도 2에 나타내었다. The mouse of each experimental group of Experimental Example 1 was anesthetized and then lyophilized to observe the spleen size and cell fidelity of the mesenteric lymph nodes. The results are shown in FIG.
도 2에서 보여주듯이, 비장 크기(2A, 2B) 및 장간막 림프절의 세포충실도(2C)를 분석한 결과, 식품 알레르기 유도 그룹(G2)이 정상 그룹(G1)에 비해 비장의 크기 및 장간막 림프절의 세포충실도가 증가하였다. 반면, 덱사메타손을 처리한 그룹(G3)의 경우에는 정상 그룹(G1)에 비해 비장의 크기가 작고, 장간막 림프절의 세포충실도가 낮은 것을 알 수 있다. 이와 달리, 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물을 처리한 그룹(G4, G5)은 비장의 크기 및 장간막 림프절의 세포충실도가 정상 그룹(G1)과 비슷한 것을 알 수 있다.As shown in FIG. 2, the analysis of the spleen size (2A, 2B) and the cell fidelity (2C) of the mesenteric lymph node revealed that the food allergy induction group (G2) Fidelity increased. On the other hand, in the dexamethasone-treated group (G3), the size of the spleen is smaller than that of the normal group (G1) and the cell fidelity of mesenteric lymph nodes is lower. In contrast, in the group (G4, G5) treated with the Syzygium formosum extract of the present invention, the size of the spleen and the cell fidelity of mesenteric lymph nodes are similar to those of the normal group (G1).
이를 통해, 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물이 면역세포의 생존율에 영향을 주지 않으면서 식품 알레르기에 대한 숙주의 면역 반응을 억제한다는 것을 알 수 있었다. Thus, it can be seen that the Syzygium formosum extract of the present invention inhibits the host immune response to food allergy without affecting the survival rate of immune cells.
<실험예 4. 식품 알레르기에 의한 소장의 조직 및 세포 변화 관찰><Experimental Example 4: Observation of tissue and cell changes in small intestine due to food allergy>
실험예 4-1. 소장의 조직 변화 관찰Experimental Example 4-1. Observation of tissue changes in small intestine
식품 알레르기에 의한 소장(small intestine)에서의 염증 관련 병변의 변화를 확인하였다. 상기 실험예 1의 각 실험 그룹의 마우스를 마취한 후 개복하여 소장을 꺼낸 후 포르말린(formalin)으로 고정시킨 후 파라핀(paraffin)으로 처리하여 조직에 파라핀을 침투시키고 포매한 후 마이크로톰으로 박절하여 조직 절편을 확보 하였다. 확보한 소장의 절편을 이용해 H&E(hematoxylin and eosin) 염색을 한 후 현미경 상에서 소장의 상태를 관찰하였고, 그 결과를 도 3에 나타내었다. Inflammatory changes in small intestine caused by food allergy were examined. After the mouse of each experimental group of Experimental Example 1 was anesthetized, the small intestine was taken out, fixed with formalin, treated with paraffin, infiltrated with paraffin and embedded in microtome, Respectively. H & E (hematoxylin and eosin) staining was performed using the obtained small intestine, and the state of the small intestine was observed under a microscope. The results are shown in FIG.
도 3에서 보여주듯이, 식품 알레르기 유도 그룹(G2)이 정상 그룹(G1)에 비해 소장의 점막하 조직 층이 두꺼워진 반면, 덱사메타손 처리 그룹(G3) 또는 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물을 처리한 그룹(G5)은 정상 그룹과 비슷한 것을 알 수 있다.As shown in FIG. 3, the food allergy inducing group (G2) is thicker in the submucosa of the small intestine than the normal group (G1), whereas the dexamethasone treatment group (G3) or the Syzygium formosum extract (G5) treated in the same manner as the normal group.
이를 통해, 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물이 알레르기에 의한 염증을 완화시킨다는 것을 알 수 있었다.Thus, it can be seen that the Syzygium formosum extract of the present invention alleviates inflammation caused by allergy.
실험예 4-2. 소장의 비만세포 관찰Experimental Example 4-2. Observation of mast cell in small intestine
알레르기 반응을 유발한다고 알려진 비만세포를 관찰함으로써 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물의 알레르기 예방 및 치료 효과를 확인하였다. By observing mast cells known to induce an allergic reaction, the effect of the Syzygium formosum extract of the present invention on the prevention and treatment of allergy was confirmed.
상기 실험예 4-1에서 확보한 소장의 조직 절편을 이용하여 비만세포를 관찰하기 위해 톨루이딘(toluidine)으로 염색하고, 현미경 상에서 비만 세포 수를 측정하여 그 결과를 도 4에 나타내었다. The tissue sections of the small intestine obtained in Experimental Example 4-1 were stained with toluidine to observe mast cells, and the number of mast cells was measured under a microscope. The results are shown in FIG.
도 4에서 보여주듯이, 식품 알레르기 유도 그룹(G2)이 정상 그룹(G1)에 비해 소장 내의 비만세포의 수가 증가하였다. 덱사메타손(G3)과 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물(G5)을 처리한 경우는 알레르기 유도에 의해 증가된 비만세포 수가 감소하였다. As shown in FIG. 4, the number of mast cells in the small intestine was increased in the food allergy induction group (G2) compared with the normal group (G1). When treated with dexamethasone (G3) and the Syzygium formosum extract (G5) of the present invention, the number of mast cells increased by allergy induction was decreased.
실험예 4-3. 소장의 호산구(eosinophils) 관찰EXPERIMENTAL EXAMPLE 4-3. Observation of eosinophils in the small intestine
호산구는 식품 알레르기에 중요한 역할을 한다고 알려져 있다. 즉, 호산구는 소장에서 알레르기성 염증을 유발시킨다. 이에 소장에서의 호산구 변화를 관찰함으로써, 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물의 알레르기 예방 및 치료 효과를 확인하였다. Eosinophils are known to play an important role in food allergy. In other words, eosinophils cause allergic inflammation in the small intestine. By observing eosinophil changes in the small intestine, the effect of the Syzygium formosum extract of the present invention on the prevention and treatment of allergy was confirmed.
상기 실험예 4-1에서 확보한 소장의 조직 절편을 에오신(eosin)으로 염색하여, 소장에서의 호산구 침윤을 관찰하였고, 그 결과를 도 5에 나타내었다. The tissue section of the small intestine obtained in Experimental Example 4-1 was stained with eosin to observe eosinophil infiltration in the small intestine. The results are shown in Fig.
도 5에서 보여주듯이, 식품 알레르기 유도 그룹(G2)이 정상 그룹(G1)에 비해 소장 내의 호산구 침윤이 증가하였고, 덱사메타손(G3)과 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물(G5)을 처리한 경우는 호산구의 침윤이 감소하였다. As shown in FIG. 5, eosinophil infiltration in the small intestine was increased in the food allergy induction group (G2) compared to the normal group (G1), and dexamethasone (G3) and the Syzygium formosum extract (G5) When treated, eosinophil infiltration decreased.
이를 통해, 본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물이 식품에 의한 알레르기를 예방 또는 치료할 수 있음을 알 수 있다. Thus, it can be seen that the Syzygium formosum extract of the present invention can prevent or treat food allergy.
<제제예 1. 약학적 제제>≪ Formulation Example 1 >
제제예 1-1. 정제의 제조Formulation Example 1-1. Manufacture of tablets
본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물 200g을 락토오스 175.9g, 감자전분 180g 및 콜로이드성 규산 32g과 혼합하였다. 이 혼합물에 10% 젤라틴 용액을 첨가시킨 후, 분쇄해서 14 메쉬체를 통과시켰다. 이것을 건조시키고 여기에 감자전분 160g, 활석 50g 및 스테아린산 마그네슘 5g을 첨가해서 얻은 혼합물을 정제로 만들었다. 200 g of the Syzygium formosum extract of the present invention was mixed with 175.9 g of lactose, 180 g of potato starch and 32 g of colloidal silicic acid. To this mixture was added a 10% gelatin solution, which was pulverized and passed through a 14-mesh sieve. This was dried, and a mixture obtained by adding 160 g of potato starch, 50 g of talc and 5 g of magnesium stearate was made into tablets.
제제예 1-2. 주사액제의 제조Formulation Example 1-2. Injection preparation
본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물 1g, 염화나트륨 0.6g 및 아스코르브산 0.1g을 증류수에 용해시켜서 100㎖를 만들었다. 이 용액을 병에 넣고 20℃에서 30분간 가열하여 멸균시켰다.1 g of the Syzygium formosum extract of the present invention, 0.6 g of sodium chloride and 0.1 g of ascorbic acid were dissolved in distilled water to make 100 ml. This solution was placed in a bottle and sterilized by heating at 20 DEG C for 30 minutes.
<제제예 2. 식품 제조><Formulation Example 2: Food Preparation>
제제예 2-1. 조리용 양념의 제조Formulation Example 2-1. Manufacture of cooking seasonings
본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물을 조리용 양념에 1 중량%로 첨가하여 건강 증진용 조리용 양념을 제조하였다. Syzygium formosum extract of the present invention was added to the cooking sauce in an amount of 1% by weight to prepare a cooking sauce for health promotion.
제제예 2-2. 밀가루 식품의 제조Formulation Example 2-2. Manufacture of flour food products
본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물을 밀가루에 0.1 중량%로 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다. Syzygium formosum extract of the present invention was added to wheat flour in an amount of 0.1 wt%, and bread, cake, cookies, crackers and noodles were prepared using this mixture to prepare a food for health promotion.
제제예 2-3. 스프 및 육즙(gravies)의 제조Preparation Example 2-3. Manufacture of soups and gravies
본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물을 스프 및 육즙에 0.1 중량%로 첨가하여 건강 증진용 수프 및 육즙을 제조하였다. Syzygium formosum extract of the present invention was added to the soup and juice at 0.1 wt% to prepare health promotion soup and juice.
제제예 2-4. 유제품(dairy products)의 제조Formulation Example 2-4. Manufacture of dairy products
본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물을 우유에 0.1 중량%로 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다. Syzygium formosum extract of the present invention was added to milk in an amount of 0.1% by weight and various dairy products such as butter and ice cream were prepared using the milk.
제제예 2-5. 야채주스 제조Formulation Example 2-5. Vegetable juice manufacturing
본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물 0.5g을 토마토주스 또는 당근주스 1,000㎖에 가하여 건강 증진용 야채주스를 제조하였다.0.5 g of the Syzygium formosum extract of the present invention was added to 1,000 ml of tomato juice or carrot juice to prepare health promotion vegetable juice.
제제예 2-6. 과일주스 제조Formulation Example 2-6. Manufacture of fruit juice
본 발명의 시지지움 포르모슘(Syzygium formosum) 추출물 0.1g을 사과주스 또는 포도주스 1,000㎖에 가하여 건강 증진용 과일주스를 제조하였다.0.1 g of Syzygium formosum extract of the present invention was added to 1,000 ml of apple juice or grape juice to prepare fruit juice for health promotion.
Claims (12)
상기 추출물은 시지지움 포르모슘(Syzygium formosum)의 잎에 물, C1 내지 C4의 저급 알코올 또는 이들의 혼합용액을 용매로 하여 추출한 추출물인 것을 특징으로 하는 알레르기 질환의 예방 또는 치료용 조성물. The method according to claim 1,
Wherein the extract is an extract obtained by extracting water from leaves of Syzygium formosum with water, C1 to C4 lower alcohols or a mixed solution thereof as a solvent.
상기 추출물은 시지지움 포르모슘(Syzygium formosum)의 잎에 메탄올을 용매로 하여 추출한 추출물인 것을 특징으로 하는 알레르기 질환의 예방 또는 치료용 조성물. 3. The method of claim 2,
Wherein the extract is an extract obtained by extracting Syzygium formosum with leaves of methanol as a solvent.
상기 알레르기는 꽃가루, 약물, 식물성 섬유, 세균, 식품, 염색약 및 화학 물질로 이루어진 군에서 선택된 1종 이상에 의해 유도되는 것을 특징으로 하는 알레르기 질환의 예방 또는 치료용 조성물. 4. The method according to any one of claims 1 to 3,
Wherein the allergy is induced by at least one selected from the group consisting of pollen, a drug, a vegetable fiber, a bacterium, a food, a hair dye, and a chemical substance.
상기 알레르기는 식품에 의해 유도되는 알레르기인 것을 특징으로 하는 알레르기 질환의 예방 또는 치료용 조성물. 5. The method of claim 4,
The composition for preventing or treating an allergic disease according to claim 1, wherein the allergen is an allergen induced by food.
상기 알레르기 질환은 두드러기, 아나필락시스, 알레르기성 비염, 기관지천식 및 아토피성 피부염으로 이루어진 군에서 선택되는 1종 이상인 것을 특징으로 하는 알레르기 질환의 예방 또는 치료용 조성물. 4. The method according to any one of claims 1 to 3,
Wherein the allergic disease is at least one selected from the group consisting of urticaria, anaphylaxis, allergic rhinitis, bronchial asthma and atopic dermatitis.
상기 추출물은 시지지움 포르모슘(Syzygium formosum)의 잎에 물, C1 내지 C4의 저급 알코올 또는 이들의 혼합용액을 용매로 하여 추출한 추출물인 것을 특징으로 하는 알레르기 질환의 예방 또는 개선용 건강기능식품. 8. The method of claim 7,
Wherein the extract is an extract obtained by extracting Syzygium formosum with leaves, water, C1 to C4 lower alcohols or a mixed solution thereof as a solvent.
상기 추출물은 시지지움 포르모슘(Syzygium formosum)의 잎에 메탄올을 용매로 하여 추출한 추출물인 것을 특징으로 하는 알레르기 질환의 예방 또는 개선용 건강기능식품. 9. The method of claim 8,
Wherein the extract is an extract obtained by extracting methanol with Syzygium formosum as a solvent. The present invention relates to a health functional food for preventing or ameliorating allergic diseases.
상기 알레르기는 꽃가루, 약물, 식물성 섬유, 세균, 식품, 염색약 및 화학 물질로 이루어진 군에서 선택된 1종 이상에 의해 유도되는 것을 특징으로 하는 알레르기 질환의 예방 또는 개선용 건강기능식품. 10. The method according to any one of claims 7 to 9,
Wherein said allergies are induced by at least one member selected from the group consisting of pollen, drug, vegetable fiber, bacteria, food, hair dye, and chemical substances.
상기 알레르기는 식품에 의해 유도되는 알레르기인 것을 특징으로 하는 알레르기 질환의 예방 또는 개선용 건강기능식품. 9. The method of claim 8,
Wherein the allergen is an allergen induced by a food.
상기 알레르기 질환은 두드러기, 아나필락시스, 알레르기성 비염, 기관지천식 및 아토피성 피부염으로 이루어진 군에서 선택되는 1종 이상인 것을 특징으로 하는 알레르기 질환의 예방 또는 개선용 건강기능식품.
10. The method according to any one of claims 7 to 9,
Wherein said allergic disease is at least one selected from the group consisting of urticaria, anaphylaxis, allergic rhinitis, bronchial asthma and atopic dermatitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160070800A KR101704996B1 (en) | 2016-06-08 | 2016-06-08 | Composition comprising an extraction of Syzygium formosum for preventing or treating of allergy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160070800A KR101704996B1 (en) | 2016-06-08 | 2016-06-08 | Composition comprising an extraction of Syzygium formosum for preventing or treating of allergy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101704996B1 true KR101704996B1 (en) | 2017-02-09 |
Family
ID=58154489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160070800A KR101704996B1 (en) | 2016-06-08 | 2016-06-08 | Composition comprising an extraction of Syzygium formosum for preventing or treating of allergy |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101704996B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020076101A1 (en) * | 2018-10-11 | 2020-04-16 | (주)카보엑스퍼트 | Skin whitening, anti-bacterial or anti-atopic composition, containing syzygium formosum extract as active ingredient |
| KR20220065182A (en) | 2020-11-13 | 2022-05-20 | (주)내츄럴코리아 | Cosmetic composition containing Syzygium formosum extract and resorcinol derivatives stabilized in nano-liposome |
| WO2022114470A1 (en) * | 2020-11-27 | 2022-06-02 | (주)카보엑스퍼트 | Composition comprising fraction of syzygium formosum extract as active ingredient |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130068307A (en) | 2011-12-15 | 2013-06-26 | 조선대학교산학협력단 | 15- 15 Composition for inhibiting 15-hydroxyprostaglandin dehydrogenase15-PGDH comprising plant extract |
-
2016
- 2016-06-08 KR KR1020160070800A patent/KR101704996B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130068307A (en) | 2011-12-15 | 2013-06-26 | 조선대학교산학협력단 | 15- 15 Composition for inhibiting 15-hydroxyprostaglandin dehydrogenase15-PGDH comprising plant extract |
Non-Patent Citations (17)
| Title |
|---|
| Bock S.A., Prospective appraisal of complaints of adverse reactions to foods in children during the first 3 years of life, Pediatrics, 79, 683-688, 1987. |
| Grundy J., et al., Rising prevalence of allergy to peanut in children: Data from 2 sequential cohorts, J. Allergy Clin. Immunol., 110, 784-789, 2002. |
| Hill D.J., et al., Confirmation of the association between high levels of immunoglobulin E food sensitization and eczema in infancy: an international study, Clin. Exp. Allergy, 38, 161-168, 2008. |
| Kjaer H.F., et al., The prevalence of allergic diseases in an unselected group of 6-year-old children. The DARC birth cohort study, Pediatr Allergy Immunol., 19, 737-745, 2008. |
| Norwak-Wegrzyn A., et al., Adverse reactions to foods, Med. Clin. N. Am., 90, 97-127, 2006. |
| Ortolani C., et al., IgE-mediated allergy from vegetable allergens, Ann. Allergy, 71, 470-476, 1993. |
| Sampson H.A., Food allergy, J. Allergy Clin. Immunol., 111(Suppl 2), 540-547, 2003. |
| Sampson H.A., Food allergy, Part I: Immunopathogenesis and clinical disorders, J. Allergy Clin, Immunol., 103, 717-728, 1999. |
| Sicherer S.H., et al., Food allergy: Recent advances in pathophysiology and treatment, Annu. Rev. Med., 60, 261-277, 2009. |
| Sicherer S.H., Food protein-induced enterocolitis syndrome: case presentations and managements lesson, J. Allergy Clin. Immuol., 115, 149-156, 2005. |
| Venter C., et al., Prevalence and cumulative incidence of food hypersensitivity in the first 3 years of life, Allergy, 63, 354-359, 2008. |
| Venter C., et al., Prevalence of sensitization reported and objectively assessed food hypersensitivity among 6-year-old children: a population-based study, Pediatr Allergy Immunol., 17, 356-363, 2006. |
| 박용민, 식품알레르기의 개요, 식품과학과 산업, 48(1), 1-9, 2015. |
| 비특허문헌1: NATURAL PRODUCT SCIENCES * |
| 비특허문헌2: JOURNAL OF ETHNOPHARMACOLOGY * |
| 비특허문헌3: BRAZILIA JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH* * |
| 최선희, et al., 소아의 식품 알레르기, J. Korean Med., Assoc., 52(11), 1090-1099, 2009. |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020076101A1 (en) * | 2018-10-11 | 2020-04-16 | (주)카보엑스퍼트 | Skin whitening, anti-bacterial or anti-atopic composition, containing syzygium formosum extract as active ingredient |
| KR20200041798A (en) * | 2018-10-11 | 2020-04-22 | (주)카보엑스퍼트 | A composition comprising extract of Syzygium formosum for skin whitening, anti-bacterial or anti-atopic |
| KR20210054498A (en) * | 2018-10-11 | 2021-05-13 | (주)카보엑스퍼트 | A composition comprising extract of Syzygium formosum for anti-bacterial |
| KR102251190B1 (en) * | 2018-10-11 | 2021-05-14 | (주)카보엑스퍼트 | A composition comprising extract of Syzygium formosum for skin whitening |
| KR102328237B1 (en) * | 2018-10-11 | 2021-11-22 | (주)카보엑스퍼트 | A composition comprising extract of Syzygium formosum for anti-bacterial |
| KR20220065182A (en) | 2020-11-13 | 2022-05-20 | (주)내츄럴코리아 | Cosmetic composition containing Syzygium formosum extract and resorcinol derivatives stabilized in nano-liposome |
| WO2022114470A1 (en) * | 2020-11-27 | 2022-06-02 | (주)카보엑스퍼트 | Composition comprising fraction of syzygium formosum extract as active ingredient |
| KR20220074362A (en) * | 2020-11-27 | 2022-06-03 | (주)카보엑스퍼트 | Composition comprising a fraction of Sizigium formosium extract as an active ingredient |
| KR102440534B1 (en) | 2020-11-27 | 2022-09-06 | (주)카보엑스퍼트 | Composition comprising a fraction of Sizigium formosium extract as an active ingredient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101893754B1 (en) | Composition comprising inotodiol for preventing or treating of allergy | |
| US8518462B2 (en) | Compound comprising extracts or fractions of chrysanthemum boreale makino having anti-inflammation activity | |
| KR101704996B1 (en) | Composition comprising an extraction of Syzygium formosum for preventing or treating of allergy | |
| KR101756775B1 (en) | Compositions for treating, improving or preventing for diseases derived from helicobacter pylori | |
| KR102607602B1 (en) | Synergistic composition for osteoarthritis | |
| KR101972074B1 (en) | Composition comprising bee venom isolated from Vespa mandarinia worker for prevention or treating Alzheimer's disease | |
| KR102293111B1 (en) | Composition for improving cognitive function, memory and activity comprising mixture of Schizandra chinensis extract and ascorbic acid as effective component | |
| KR101427290B1 (en) | Pharmaceutical composition for prevention and treatment of chronic obstructive pulmonary disease comprising extract of Phyllostachys nigra Munro var. henosis Stapf as an active ingredient | |
| JP7277571B2 (en) | Composition for prevention or treatment of allergic diseases, containing an inotodiol compound as an active ingredient | |
| KR101972070B1 (en) | Composition comprising bee venom isolated from Vespa mandarinia worker for prevention or treating avian influenza | |
| KR102194336B1 (en) | Immune-enhancing composition comprising subcritical water extract of pepper leaf as effective component | |
| KR102271471B1 (en) | Composition for preventing and treating allergy comprising asiatic tearthumb | |
| KR101615923B1 (en) | Composition Comprising Extracts of Boehmeria tricuspis, Angelica decursiva or Arctium lappa Having Anti-allergy or Anti-inflammation | |
| KR102234860B1 (en) | Composition for prevention and treatment of muscle atrophy comprising lespedeza bicolor extract | |
| KR101947276B1 (en) | Composition for immune enhanvement comprising sargassum coreanum enzymatic extract | |
| KR20160022190A (en) | A composition for the treatment or prevention of asthma comprising erythronium japonicum | |
| KR20150074260A (en) | Antiallergic agents comprising extracts from rhamnus davurica | |
| KR20190136543A (en) | Compostion for preventing or treating the Developmental Disability comprising Humulus japonicus extract as active ingredient | |
| KR102506461B1 (en) | A composition for improving Inflammatory bowel disease comprising Tetraselmis chuii | |
| KR20090019396A (en) | Pharmaceutical compositions for preventing and treating allergy comprising small black soybean | |
| KR102526718B1 (en) | Composition for the preventing and improving menopausal disorder, comprising extract of acer tegmentosum maxim and extract of Rumecis Radix | |
| KR101323626B1 (en) | Compositions comprising an extract of Phellodendri Cortex for the prevention or treatment of pancreatitis | |
| KR102291073B1 (en) | Composition for Anti-inflammation and Anti-allergy Using an Extract of Bistorta manshuriensis | |
| KR102206870B1 (en) | Combined Formulation for Prevention or Treatment of Atopic Dermatitis and Process for Thereof | |
| KR101887585B1 (en) | A composition for preventing or treating the cognitive dysfunction or neuroinflammation comprising Ambrosia artemisiifolia extract or a fraction thereof as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20200130 Year of fee payment: 4 |